Page 1

1st Quarter 2021 Results 1st Quarter 2021 Sales Worldwide Increased $ 22.3B 7.9 % Diluted Earnings Per Share Increased $ 2.32 6.9 % Excluding acquisitions / divestitures on an operational basis Worldwide Increased 6.0 % * Adjusted Diluted Earnings Per Share * Increased $ 2.59 12.6 % " Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices . The ability to deliver these results while simultaneously advancing our robust pipeline of life - enhancing medicines , products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Johnson & Johnson who strive every day to profoundly change the trajectory of health for humanity and make healthier communities for everyone , everywhere . " Alex Gorsky Chairman and Chief Executive Officer Johnson & Johnson $ 3.5 Billion $ 12.2 Billion A $ 6.6 Billion aff Worldwide Consumer Health Sales Consumer Health worldwide reported sales decreased ( 2.3 ) % or ( 3.3 ) % operationally¹ . Primary offsets to decline : LISTERINE Johnson's Aveeno . Pepcid nicorette Stelara ( ustekinumab ) Worldwide Pharmaceutical Sales Pharmaceutical worldwide reported sales increased 9.6 % or 7.1 % operationally¹ . Primary operational drivers : Erleada Uptravi ( apalutamide ) comptablets selexipag tablets in Johnson & Johnson Electrophysiology DARZALEX imbruvică ( ibrutinib ) ( daratumumab ) action or inanc infusion 130mg / 5m 400 mg / 20 m Wound Closure Note : values may have been rounded 340420 INVEGA SUSTENNA -paliperidone palmitate Worldwide Medical Devices Sales Medical Devices worldwide reported sales increased 10.9 % or 8.0 % operationally¹ . Primary operational drivers : Endocutters ZYRTEC Biosurgery Surgical Vision Tremfya ( guselkumab ) Opsumit macitentan Trauma O Energy For full financial data and non - GAAP reconciliations , please refer to Johnson & Johnson's earnings release issued on April 20 , 2021 , available at http://www.investor.jnj.com/sales-earnings.cfm . * Non - GAAP financial measure ; non - GAAP financial measures should not be considered replacements for , and should be read together with , the most comparable GAAP financial measures . ¹Non - GAAP measure ; excludes the impact of translational currency . Caution Concerning Forward - Looking Statements : This document contains " forward - looking statements " as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance . You are cautioned not to rely on these forward - looking statements , which are based on current expectations of future events . For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions , expectations , and projections expressed in any forward - looking statements , review the " Note to Investors Concerning Forward - Looking Statements " included in the Johnson & Johnson earnings release issued on April 20 , 2021 , as well as the most recently filed Johnson & Johnson Reports on Forms 10 - K and 10 - Q . Johnson & Johnson does not undertake to update any forward - looking statement as result of new information or future events or developments .